Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Kikkoman Biochemifa Company advances global health and safety through precision-driven innovation in biotech and food testing.

    Virtual Booth

    Contact Supplier

    dmfs-not-supported-m-2025-06-30

    Virtual Booth

    An Enquiry

    granules-india-limited-m-2025-07-07

    Virtual Booth

    Contact Supplier

    Allsino Pharma excels in R&D & manufacturing of RSMs, GMP intermediates, & APIs; ISO-certified, GMP-compliant, accredited by NMPA.

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-06-30

    Virtual Booth

    An Enquiry

    Menu

    Taselisib

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    2D Structure
    Also known as: Gdc-0032, 1282512-48-4, 2-(4-(2-(1-isopropyl-3-methyl-1h-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)-1h-pyrazol-1-yl)-2-methylpropanamide, Gdc 0032, Taselisib [inn], Gdc0032
    Molecular Formula
    C24H28N8O2
    Molecular Weight
    460.5  g/mol
    InChI Key
    BEUQXVWXFDOSAQ-UHFFFAOYSA-N
    FDA UNII
    L08J2O299M
    Taselisib is an orally bioavailable inhibitor of the class I phosphatidylinositol 3-kinase (PI3K) alpha isoform (PIK3CA), with potential antineoplastic activity. Taselisib selectively inhibits PIK3CA and its mutant forms in the PI3K/Akt/mTOR pathway, which may result in tumor cell apoptosis and growth inhibition in PIK3CA-expressing tumor cells. By specifically targeting class I PI3K alpha, this agent may be more efficacious and less toxic than pan PI3K inhibitors. Dysregulation of the PI3K/Akt/mTOR pathway is frequently found in solid tumors and causes increased tumor cell growth, survival, and resistance to both chemotherapy and radiotherapy. PIK3CA, which encodes the p110-alpha catalytic subunit of the class I PI3K, is mutated in a variety of cancer cell types and plays a key role in cancer cell growth and invasion.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    2-methyl-2-[4-[2-(5-methyl-2-propan-2-yl-1,2,4-triazol-3-yl)-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl]pyrazol-1-yl]propanamide
    2.1.2 InChI
    InChI=1S/C24H28N8O2/c1-14(2)32-22(27-15(3)29-32)19-13-30-8-9-34-20-10-16(6-7-18(20)21(30)28-19)17-11-26-31(12-17)24(4,5)23(25)33/h6-7,10-14H,8-9H2,1-5H3,(H2,25,33)
    2.1.3 InChI Key
    BEUQXVWXFDOSAQ-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    CC1=NN(C(=N1)C2=CN3CCOC4=C(C3=N2)C=CC(=C4)C5=CN(N=C5)C(C)(C)C(=O)N)C(C)C
    2.2 Other Identifiers
    2.2.1 UNII
    L08J2O299M
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. 2-(3-(2-(1-isopropyl-3-methyl-1h-1,2-4-triazol-5-yl)-5,6-dihydrobenzo(f)imidazo(1,2-d)(1,4)oxazepin-9-yl)-1h-pyrazol-1-yl)-2-methylpropanamide

    2. Gdc-0032

    3. Gdc0032

    4. Ro5537381

    2.3.2 Depositor-Supplied Synonyms

    1. Gdc-0032

    2. 1282512-48-4

    3. 2-(4-(2-(1-isopropyl-3-methyl-1h-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)-1h-pyrazol-1-yl)-2-methylpropanamide

    4. Gdc 0032

    5. Taselisib [inn]

    6. Gdc0032

    7. Taselisib (gdc0032)

    8. Rg-7604

    9. Rg7604

    10. Chembl2387080

    11. L08j2o299m

    12. Rg 7604

    13. 2-methyl-2-(4-{2-[3-methyl-1-(propan-2-yl)-1h-1,2,4-triazol-5-yl]-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl}-1h-pyrazol-1-yl)propanamide

    14. Taselisib [usan:inn]

    15. Unii-l08j2o299m

    16. 2-(4-(2-(1-isopropyl-3-methyl-1h-1,2,4-triazol-5-yl)-5,6-dihydrobenzo(f)imidazo(1,2-d)(1,4)oxazepin-9-yl)-1h-pyrazol-1-yl)-2-methylpropanamide

    17. Taselisibgdc-0032

    18. Taselisib (usan/inn)

    19. Taselisib [usan]

    20. Taselisib [who-dd]

    21. Taselisib (gdc-0032)

    22. Gtpl7794

    23. Schembl1485247

    24. Dtxsid00155842

    25. Hms3674g19

    26. Amy39941

    27. Bcp09253

    28. Ex-a1581

    29. Bdbm50434806

    30. Mfcd26142641

    31. Nsc777425

    32. Nsc800985

    33. S7103

    34. Zinc68267049

    35. Akos026750303

    36. Ccg-269338

    37. Cs-1817

    38. Db12108

    39. Gdc-0032, Taselisib; Rg-7604

    40. Nsc-777425

    41. Nsc-800985

    42. Sb16576

    43. Ncgc00387039-02

    44. 2-methyl-2-[4-[2-(5-methyl-2-propan-2-yl-1,2,4-triazol-3-yl)-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl]pyrazol-1-yl]propanamide

    45. Ac-32794

    46. As-10662

    47. Bg166285

    48. Hy-13898

    49. D11774

    50. J-690119

    51. Q27088940

    52. 1395408-87-3

    53. 1h-pyrazole-1-acetamide, 4-(5,6-dihydro-2-(3-methyl-1-(1-methylethyl)-1h-1,2,4-triazol-5-yl)imidazo(1,2-d)(1,4)benzoxazepin-9-yl)-.alpha.,.alpha.-dimethyl-

    54. 1h-pyrazole-1-acetamide, 4-[5,6-dihydro-2-[3-methyl-1-(1-methylethyl)-1h-1,2,4-triazol-5-yl]imidazo[1,2-d][1,4]benzoxazepin-9-yl]-alpha,alpha-dimethyl-

    55. 3-({[(3r,5r)-3-butyl-3-ethyl-7-methoxy-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,4-benzothiazepin-8-yl]methyl}amino)pentanedioic Aci D

    56. 4-[5,6-dihydro-2-[3-methyl-1-(1-methylethyl)-1h-1,2,4-triazol-5-yl]imidazo[1,2-d][1,4]benzoxazepin-9-yl]-

    57. A,

    58. A-dimethyl-1h-pyrazole-1-acetamide

    2.4 Create Date
    2011-04-12
    3 Chemical and Physical Properties
    Molecular Weight 460.5 g/mol
    Molecular Formula C24H28N8O2
    XLogP31.8
    Hydrogen Bond Donor Count1
    Hydrogen Bond Acceptor Count6
    Rotatable Bond Count5
    Exact Mass460.23352217 g/mol
    Monoisotopic Mass460.23352217 g/mol
    Topological Polar Surface Area119 Ų
    Heavy Atom Count34
    Formal Charge0
    Complexity751
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1